INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Sagent Pharmaceuticals, Inc. And Encourages...
19 Luglio 2016 - 8:02PM
Business Wire
The securities litigation law firm of Brower Piven, A
Professional Corporation, has commenced an investigation into
possible breaches of fiduciary duty and other violations of state
law by the Board of Directors of Sagent Pharmaceuticals, Inc.
(NASDAQ: SGNT) (“Sagent” or the “Company”) relating to the
proposed buyout of Sagent by Nichi-Iko Pharmaceutical Co., Ltd. The
firm’s investigation seeks to determine, among other things,
whether the Company’s Board of Directors failed to satisfy their
duties to shareholders, including whether the Board adequately
pursued alternatives to the acquisition and whether the Board
obtained the best price possible for the Company’s shares of common
stock.
Under the terms of the agreement, Sagent shareholders are
anticipated to receive $21.75 in cash for each share of Sagent
common stock held. The transaction may undervalue the Company
and would result in no real gain or a loss for many long-term
shareholders of Sagent, especially given that the Company’s 52-week
high is $26.47. Additionally, according to Yahoo!
Finance, at least one Wall Street analyst has issued a price target
for Sagent stock at $25.00 per share.
If you currently own common stock of Sagent and believe that the
proposed buyout price is too low, or you would like to learn more
about the investigation being conducted by Brower Piven, please
visit our website at
http://www.browerpiven.com/currentinvestigations.html. You may also
request more information by contacting Brower Piven either by email
at hoffman@browerpiven.com or by telephone at (410) 415-6616.
Attorneys at Brower Piven have extensive experience in
litigating securities and other class action cases and have been
advocating for the rights of shareholders since the 1980s.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160719006441/en/
Brower Piven, A Professional CorporationCharles J. Piven,
410-415-66161925 Old Valley RoadStevenson, Maryland
21153hoffman@browerpiven.com
Grafico Azioni Sagent (NASDAQ:SGNT)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Sagent (NASDAQ:SGNT)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Sagent Pharmaceuticals, Inc. (NASDAQ): 0 articoli recenti
Più Sagent Pharmaceuticals, Inc. (MM) Articoli Notizie